TL;DR
The current status of research on blood biomarkers for AD and associated neurodegenerative dementias is updated in this chapter.
This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.
Current research focused on blood protein biomarkers may reveal key clues for fully understanding the etiology of AD, enabling earlier diagnosis and monitoring of its progression, thereby paving the way for research targeting a cure.
Plasma biomarkers offer a transformative, non-invasive approach to early AD diagnosis and primary care triage, reducing reliance on CSF and PET scans and overcoming demographic and methodological limitations is essential for their widespread clinical adoption.
This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
